MX2018011836A - Conjugados de anticuerpo farmaco anti-cd70. - Google Patents
Conjugados de anticuerpo farmaco anti-cd70.Info
- Publication number
- MX2018011836A MX2018011836A MX2018011836A MX2018011836A MX2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A MX 2018011836 A MX2018011836 A MX 2018011836A
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugates
- antibody drug
- antibodies
- amino acid
- naturally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
Esta invención se refiere a anticuerpos anti-CD70 y a conjugados de anticuerpo fármaco que comprenden al menos un aminoácido codificado de manera no natural. Se describen en la presente anticuerpos aCD70 con uno o más aminoácidos codificados de manera no natural y además se describen conjugados de anticuerpo fármaco en donde los anticuerpos aCD70 de la invención se conjugan a una o más toxinas. Además se describen métodos para utilizar tales conjugados de anticuerpo fármaco de aminoácidos no naturales, incluyendo usos terapéuticos, de diagnóstico, y otros de biotecnología.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661782P | 2012-06-19 | 2012-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011836A true MX2018011836A (es) | 2020-09-14 |
Family
ID=48700005
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015878A MX359449B (es) | 2012-06-19 | 2013-06-19 | Conjugados de anticuerpo fármaco anti-cd70. |
MX2018011836A MX2018011836A (es) | 2012-06-19 | 2014-12-18 | Conjugados de anticuerpo farmaco anti-cd70. |
MX2023010178A MX2023010178A (es) | 2012-06-19 | 2014-12-18 | Conjugados de anticuerpo farmaco anti-cd70. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015878A MX359449B (es) | 2012-06-19 | 2013-06-19 | Conjugados de anticuerpo fármaco anti-cd70. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023010178A MX2023010178A (es) | 2012-06-19 | 2014-12-18 | Conjugados de anticuerpo farmaco anti-cd70. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10208123B2 (es) |
EP (2) | EP2861262B1 (es) |
JP (3) | JP6343609B2 (es) |
KR (3) | KR102490719B1 (es) |
CN (2) | CN111499684A (es) |
AU (1) | AU2013277169B2 (es) |
CA (1) | CA2877124A1 (es) |
ES (1) | ES2712648T3 (es) |
IL (1) | IL236323B (es) |
MX (3) | MX359449B (es) |
NZ (2) | NZ724593A (es) |
SG (1) | SG11201408494UA (es) |
WO (1) | WO2013192360A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AU2011291943B2 (en) | 2010-08-17 | 2015-01-22 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
NZ724593A (en) | 2012-06-19 | 2019-05-31 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
CN110143999B (zh) | 2013-03-15 | 2023-12-05 | 酵活英属哥伦比亚省公司 | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
RU2016134258A (ru) | 2013-10-15 | 2018-02-28 | Сорренто Терапьютикс Инк. | Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
KR20160125361A (ko) | 2013-12-27 | 2016-10-31 | 자임워크스 인코포레이티드 | Var2csa-약물 접합체 |
HUE047952T2 (hu) | 2014-04-25 | 2020-05-28 | Pf Medicament | Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra |
DK3134124T3 (da) | 2014-04-25 | 2019-05-06 | Pf Medicament | Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft |
US10391168B1 (en) * | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
MX2017003476A (es) | 2014-09-17 | 2017-08-02 | Zymeworks Inc | Compuestos citotoxicos y anti-mitoticos, y metodos para usar los mismos. |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
WO2016123412A1 (en) | 2015-01-28 | 2016-08-04 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
JP6607634B2 (ja) * | 2015-09-04 | 2019-11-20 | 学校法人 岩手医科大学 | 腫瘍の再発を抑制するための標的分子としてのtaf15遺伝子およびその産物 |
US10233212B2 (en) | 2015-11-03 | 2019-03-19 | Industrial Technology Research Institute | Compounds, linker-drugs and ligand-drug conjugates |
US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
LT3423105T (lt) | 2016-03-02 | 2021-09-10 | Eisai R&D Management Co., Ltd. | Antikūno-vaisto konjugatai eribulino pagrindu ir jų panaudojimo būdai |
MY193457A (en) | 2017-02-08 | 2022-10-14 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
KR20240063184A (ko) | 2017-06-02 | 2024-05-09 | 암브룩스, 인코포레이티드 | 비천연 아미노산 함유 단백질 생성을 촉진하는 방법 및 조성물 |
CN108404138B (zh) * | 2018-03-09 | 2020-04-17 | 中国药科大学 | 一种靶向cd24单克隆抗体与二乙胺偶氮鎓二醇盐的偶联物及其应用 |
JP2020019723A (ja) * | 2018-07-30 | 2020-02-06 | 国立大学法人 鹿児島大学 | 抗CD70抗体とIgG結合ペプチドの複合体 |
CN109232712B (zh) * | 2018-08-21 | 2021-08-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体药物偶联物的中间体的制备方法 |
US20210317213A1 (en) | 2018-08-28 | 2021-10-14 | Ambrx, Inc. | Anti-CD3 Antibody Folate Bioconjugates and Their Uses |
CN109799352B (zh) * | 2019-01-29 | 2022-03-08 | 北京健坤禾润科技有限公司 | 化学发光试剂及其在免疫检测中应用 |
WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
WO2023000171A1 (zh) * | 2021-07-20 | 2023-01-26 | 浙江新码生物医药有限公司 | 一种含有抗her2-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
CN113754769B (zh) * | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd70的抗体及其制备和用途 |
CN116023500B (zh) * | 2021-10-25 | 2023-07-04 | 重庆精准生物技术有限公司 | 一种靶向全人源化cd70的嵌合抗原受体及其应用 |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
CN115708810A (zh) * | 2022-11-03 | 2023-02-24 | 浙江新码生物医药有限公司 | 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
JP2002505338A (ja) | 1998-03-05 | 2002-02-19 | カイロン コーポレイション | 生物学的に活性な分子の血清半減期を増加するための方法 |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US7642085B2 (en) | 2002-12-22 | 2010-01-05 | The Scripps Research Institute | Protein arrays |
JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2006113909A2 (en) * | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
ES2545533T3 (es) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Composiciones y métodos para modificación de biomoléculas |
CN101341118A (zh) * | 2004-12-22 | 2009-01-07 | Ambrx公司 | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途 |
BRPI0516385B1 (pt) | 2004-12-22 | 2021-07-20 | Ambrx, Inc. | Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo |
JP2009509510A (ja) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Cd70に対するヒトモノクローナル抗体 |
JP2010513306A (ja) | 2006-12-14 | 2010-04-30 | メダレックス インコーポレーティッド | Cd70に結合するヒト抗体およびその使用 |
CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
CA2672205A1 (en) * | 2006-12-18 | 2008-06-26 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
WO2009001364A2 (en) * | 2007-06-28 | 2008-12-31 | Capsutech Ltd | Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers |
MX371526B (es) * | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
WO2012166560A1 (en) * | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
WO2013068874A1 (en) * | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
EP2858676B1 (en) | 2012-06-07 | 2019-03-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
NZ724593A (en) | 2012-06-19 | 2019-05-31 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
KR101677602B1 (ko) | 2012-07-14 | 2016-11-18 | 인디언 오일 코퍼레이션 리미티드 | 1,2-페닐렌디오에이트를 내부 공여체로서 포함하는 지글러-나타 촉매계 및 그의 제조 방법 |
US9796854B1 (en) * | 2016-07-07 | 2017-10-24 | Intuitive Surgical Operations, Inc. | Method of synthesizing near IR, closed chain sulfo-cyanine dyes |
-
2013
- 2013-06-19 NZ NZ724593A patent/NZ724593A/en unknown
- 2013-06-19 KR KR1020217038390A patent/KR102490719B1/ko active IP Right Grant
- 2013-06-19 SG SG11201408494UA patent/SG11201408494UA/en unknown
- 2013-06-19 CN CN201911336781.0A patent/CN111499684A/zh active Pending
- 2013-06-19 JP JP2015518566A patent/JP6343609B2/ja active Active
- 2013-06-19 ES ES13732069T patent/ES2712648T3/es active Active
- 2013-06-19 EP EP13732069.3A patent/EP2861262B1/en active Active
- 2013-06-19 CN CN201380042979.2A patent/CN104619351B/zh active Active
- 2013-06-19 MX MX2014015878A patent/MX359449B/es active IP Right Grant
- 2013-06-19 WO PCT/US2013/046669 patent/WO2013192360A1/en active Application Filing
- 2013-06-19 US US14/410,021 patent/US10208123B2/en active Active
- 2013-06-19 NZ NZ703581A patent/NZ703581A/en active IP Right Revival
- 2013-06-19 EP EP18202270.7A patent/EP3488870B1/en active Active
- 2013-06-19 CA CA2877124A patent/CA2877124A1/en active Pending
- 2013-06-19 AU AU2013277169A patent/AU2013277169B2/en active Active
- 2013-06-19 KR KR1020157001414A patent/KR102190832B1/ko active IP Right Grant
- 2013-06-19 KR KR1020207035018A patent/KR102332435B1/ko active IP Right Grant
-
2014
- 2014-12-17 IL IL236323A patent/IL236323B/en active IP Right Grant
- 2014-12-18 MX MX2018011836A patent/MX2018011836A/es unknown
- 2014-12-18 MX MX2023010178A patent/MX2023010178A/es unknown
-
2018
- 2018-05-21 JP JP2018096862A patent/JP6756774B2/ja active Active
- 2018-12-18 US US16/224,346 patent/US11459392B2/en active Active
-
2020
- 2020-06-02 JP JP2020096365A patent/JP7183215B2/ja active Active
-
2022
- 2022-08-29 US US17/898,384 patent/US20230295320A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018011836A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
MX2019002732A (es) | Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata. | |
WO2014062697A3 (en) | Drug delivery conjugates containing unnatural amino acids and methods for using | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
BR112019008854A2 (pt) | ligantes contendo peptídeo para conjugados de anticorpo-fármaco | |
EA201390940A1 (ru) | Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком | |
PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
BR112015004022A2 (pt) | aminoácidos modificados compreendendo um grupo azido | |
TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
EA201491441A1 (ru) | Композиции конъюгата xten и способы их получения | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
WO2011113019A3 (en) | Ctla4 proteins and their uses | |
BR112012032778A2 (pt) | "proteínas multiespecíficas e multivalentes" | |
EP4276180A3 (en) | Clostridium histolyticum enzyme | |
EA201690782A1 (ru) | Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты | |
WO2013177593A3 (en) | Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies | |
AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
UA107836C2 (uk) | Метод лікування хвороби альцгеймера | |
WO2014179184A8 (en) | Compositions for inducing immune tolerance to coagulation factor proteins | |
CL2015001849A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos | |
EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
WO2014039074A3 (en) | Therapeutic compositions and related methods | |
MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
UA99801C2 (ru) | Белковая конструкция, которая включает модифицированный полипептид casb7439 |